MY176987A - 2-substituted cephem compounds - Google Patents

2-substituted cephem compounds

Info

Publication number
MY176987A
MY176987A MYPI2015701345A MYPI2015701345A MY176987A MY 176987 A MY176987 A MY 176987A MY PI2015701345 A MYPI2015701345 A MY PI2015701345A MY PI2015701345 A MYPI2015701345 A MY PI2015701345A MY 176987 A MY176987 A MY 176987A
Authority
MY
Malaysia
Prior art keywords
cephem compounds
compounds
substituted cephem
substituted
pharmaceutical compositions
Prior art date
Application number
MYPI2015701345A
Inventor
Xiangmin Liao
Neil David Pearson
Israil Pendrak
Reema Thalgi
Kenji Yamawaki
Katsuki Yokoo
Jun Sato
Hiroki Kusano
Toshiaki Aoki
Original Assignee
Glaxo Group Ltd
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49955387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY176987(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd, Shionogi & Co filed Critical Glaxo Group Ltd
Publication of MY176987A publication Critical patent/MY176987A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/48—Methylene radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/48—Methylene radicals, substituted by hetero rings
    • C07D501/50—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by an aliphatic carboxylic acid, which is substituted by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The compounds of the subject invention are related to 2-substituted cephem compounds, which have a wide antimicrobial spectrum, in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical compositions comprising the same.
MYPI2015701345A 2012-10-29 2013-10-29 2-substituted cephem compounds MY176987A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261719523P 2012-10-29 2012-10-29
PCT/IB2013/002423 WO2014068388A1 (en) 2012-10-29 2013-10-29 2 substituted cephem compounds

Publications (1)

Publication Number Publication Date
MY176987A true MY176987A (en) 2020-08-31

Family

ID=49955387

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015701345A MY176987A (en) 2012-10-29 2013-10-29 2-substituted cephem compounds

Country Status (38)

Country Link
US (2) US20150299223A1 (en)
EP (1) EP2917223B1 (en)
JP (1) JP6316830B2 (en)
KR (1) KR20150081428A (en)
CN (2) CN107652310A (en)
AR (1) AR093261A1 (en)
AU (2) AU2013340469B2 (en)
BR (2) BR112015009460A2 (en)
CA (1) CA2889746A1 (en)
CL (1) CL2015001084A1 (en)
CR (1) CR20150224A (en)
CY (1) CY1121721T1 (en)
DK (1) DK2917223T3 (en)
EA (1) EA031881B1 (en)
ES (1) ES2717923T3 (en)
HK (1) HK1214826A1 (en)
HR (1) HRP20190603T1 (en)
HU (1) HUE042664T2 (en)
IL (1) IL238149A (en)
LT (1) LT2917223T (en)
MA (1) MA38039A1 (en)
ME (1) ME03359B (en)
MX (1) MX365534B (en)
MY (1) MY176987A (en)
NZ (1) NZ628527A (en)
PE (1) PE20151204A1 (en)
PH (2) PH12015500914A1 (en)
PL (1) PL2917223T3 (en)
PT (1) PT2917223T (en)
RS (1) RS58611B1 (en)
SG (2) SG10201703589TA (en)
SI (1) SI2917223T1 (en)
TR (1) TR201904001T4 (en)
TW (1) TWI625333B (en)
UA (1) UA117666C2 (en)
UY (1) UY35103A (en)
WO (1) WO2014068388A1 (en)
ZA (1) ZA201502174B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013339040A1 (en) * 2012-10-29 2015-04-30 Shionogi & Co., Ltd. Processes for production of intermediates for 2-alkyl cephem compounds
WO2014104148A1 (en) * 2012-12-26 2014-07-03 塩野義製薬株式会社 Cephem compound
JP6377570B2 (en) * 2014-04-28 2018-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Pharmaceutical composition containing 2-substituted cephem compound
SI3190115T1 (en) 2014-09-04 2021-11-30 Shionogi & Co., Ltd. Salt of cephalosporin derivative, crystalline solid form of same and method for producing same
CN107074824B (en) * 2014-09-05 2021-01-08 基因泰克公司 Phthalazine derivatives of formula (I) as PCAF and GCN5 inhibitors for the treatment of cancer
JP6814730B2 (en) 2014-09-05 2021-01-20 ジェネンテック， インコーポレイテッド Therapeutic compounds and their use
CN104529735A (en) * 2014-12-08 2015-04-22 苏州施亚生物科技有限公司 1-(5-bromo-4-chloro-2-fluorophenyl)-ethanone synthesis method
JP6659703B2 (en) 2015-01-09 2020-03-04 ジェネンテック， インコーポレイテッド Pyridazinone derivatives and their use in the treatment of cancer
US10464896B2 (en) 2015-06-11 2019-11-05 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
WO2016200827A1 (en) * 2015-06-11 2016-12-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor
US9765026B2 (en) * 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
AU2016367284C1 (en) * 2015-12-10 2018-09-20 Naeja-Rgm Pharmaceuticals Ulc Cephem compounds, their production and use
AU2018219226A1 (en) 2017-02-07 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
CN106966914B (en) * 2017-05-04 2019-02-22 无锡捷化医药科技有限公司 A kind of preparation method of the chloro- 2- aminoacetophenone of the bromo- 4- of 5-
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
CN108892639B (en) * 2018-08-13 2021-05-14 云南民族大学 Efficient and environment-friendly method for preparing quinolone compounds
CN113024581A (en) * 2020-03-04 2021-06-25 刀鹏 Synthesis method of cefepime hydrochloride
CA3204655A1 (en) * 2021-01-12 2022-07-21 Jian Huang Cephalosporin antibacterial compound and preparation method therefor
CN113698365A (en) * 2021-08-30 2021-11-26 成都大学 Preparation method of cefditoren side chain
CN116514679A (en) * 2023-04-03 2023-08-01 南京工业大学 Palladium-catalyzed sp with low-cost and high-efficiency quaternary ammonium nitrate as oxidant 2 And sp (sp) 3 Carbon hydrogen bond alkenylation method

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3487079A (en) * 1966-01-14 1969-12-30 Bristol Myers Co Certain alpha-amino bicyclic beta-lactam carboxylic acids
US3926983A (en) * 1974-08-30 1975-12-16 Squibb & Sons Inc 3-Heterothio{8 (alkoxycarbonyl)thioacetyl{9 cephalosporanic derivatives
US4268509A (en) 1978-07-10 1981-05-19 Fujisawa Pharmaceutical Co., Ltd. New cephem compounds and processes for preparation thereof
JPS5511600A (en) * 1978-07-10 1980-01-26 Fujisawa Pharmaceut Co Ltd Cephem compound, its salt, their preparation and remedy and prophylactic for microbism containing mainly the same
JPS56118085A (en) * 1980-02-25 1981-09-16 Takeda Chem Ind Ltd 2-methylcephalosporin derivative and its preparation
GB8816519D0 (en) 1987-07-23 1988-08-17 Ici Plc Antibiotic compounds
JPH0228185A (en) 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd Cephalosporin compound and synthetic intermediate thereof
PH25965A (en) 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
GB8813945D0 (en) 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
US5143910A (en) 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5095012A (en) * 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
DE69431691T2 (en) 1993-04-16 2003-08-21 Basilea Pharmaceutica Ag Binni Cephalosporin derivatives
EP0838465A1 (en) 1996-10-22 1998-04-29 F. Hoffmann-La Roche Ag Pyridinium-substituted (lactamylvinyl)cephalosporin derivatives, their preparation and their use as antibiotics
DE69737382T2 (en) 1996-11-06 2007-10-31 Basilea Pharmaceutica Ag Vinyl-pyrrolidinone cephalosporin derivatives
JP2003078440A (en) 2001-08-30 2003-03-14 Kyocera Corp High frequency switch circuit
TW200305422A (en) * 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
JP4557859B2 (en) 2005-09-29 2010-10-06 富士通株式会社 Frequency division multiplexing transmission / reception apparatus and transmission / reception method
JP2009530228A (en) 2006-03-16 2009-08-27 アステラス製薬株式会社 Use as cephem compounds and antibacterial agents
EP2341053B1 (en) * 2008-10-31 2016-01-13 Shionogi&Co., Ltd. Cephalosporin having catechol group
CN102918047A (en) * 2010-04-05 2013-02-06 盐野义制药株式会社 Cephem compound having pseudo-catechol group
EP2557082A4 (en) * 2010-04-05 2013-08-28 Shionogi & Co Cephem compound having catechol group
US9085589B2 (en) * 2010-04-28 2015-07-21 Shionogi & Co., Ltd. Cephem derivative
US8785467B2 (en) * 2010-09-30 2014-07-22 Merck Sharp & Dohme Corp. Alkoxy pyrimidine PDE10 inhibitors
CA2833121A1 (en) * 2011-04-28 2012-11-01 Shionogi & Co., Ltd. Novel cephem compound having catechol or pseudo-catechol structure
CN103619853A (en) * 2011-06-27 2014-03-05 盐野义制药株式会社 Cephem compound having pyridinium group
TWI547496B (en) 2011-10-04 2016-09-01 葛蘭素集團公司 Antibacterial compounds
CN103958527A (en) * 2011-10-04 2014-07-30 盐野义制药株式会社 Cephem derivative having catechol group
AU2013339040A1 (en) 2012-10-29 2015-04-30 Shionogi & Co., Ltd. Processes for production of intermediates for 2-alkyl cephem compounds

Also Published As

Publication number Publication date
PT2917223T (en) 2019-05-17
PH12015500914B1 (en) 2015-06-29
WO2014068388A1 (en) 2014-05-08
EA201590844A1 (en) 2015-09-30
HK1214826A1 (en) 2016-08-05
ES2717923T3 (en) 2019-06-26
CR20150224A (en) 2015-10-19
PH12017500755A1 (en) 2018-01-29
ME03359B (en) 2019-10-20
EA031881B1 (en) 2019-03-29
IL238149A (en) 2017-09-28
AU2017200717A1 (en) 2017-02-23
DK2917223T3 (en) 2019-04-15
TWI625333B (en) 2018-06-01
LT2917223T (en) 2019-04-10
MX2015005429A (en) 2015-07-21
MX365534B (en) 2019-06-06
CN107652310A (en) 2018-02-02
SI2917223T1 (en) 2019-05-31
US10174053B2 (en) 2019-01-08
UY35103A (en) 2014-05-30
ZA201502174B (en) 2016-01-27
SG11201502540RA (en) 2015-05-28
JP2015534995A (en) 2015-12-07
TW201431863A (en) 2014-08-16
TR201904001T4 (en) 2019-04-22
CN104884460A (en) 2015-09-02
BR112015009460A2 (en) 2017-07-04
KR20150081428A (en) 2015-07-14
SG10201703589TA (en) 2017-06-29
AU2013340469B2 (en) 2016-11-03
HRP20190603T1 (en) 2019-05-31
US20170281532A1 (en) 2017-10-05
EP2917223B1 (en) 2019-01-16
US20150299223A1 (en) 2015-10-22
UA117666C2 (en) 2018-09-10
PH12015500914A1 (en) 2015-06-29
EP2917223A1 (en) 2015-09-16
AU2013340469A1 (en) 2015-04-16
CA2889746A1 (en) 2014-05-08
PL2917223T3 (en) 2019-06-28
MA38039A1 (en) 2016-05-31
HUE042664T2 (en) 2019-07-29
AR093261A1 (en) 2015-05-27
CL2015001084A1 (en) 2015-08-28
JP6316830B2 (en) 2018-04-25
CN104884460B (en) 2017-11-03
NZ628527A (en) 2017-03-31
PE20151204A1 (en) 2015-09-03
CY1121721T1 (en) 2020-07-31
RS58611B1 (en) 2019-05-31
BR122016025225A2 (en) 2019-07-30

Similar Documents

Publication Publication Date Title
PH12017500755A1 (en) 2 substituted cephem compounds
PH12014501671B1 (en) Amidine substituted beta-lactam compounds, their preparation and use as antibacterial agents
PH12015501440B1 (en) Zinc-lysine complex
MX2014011825A (en) Isoxazole î²-lactamase inhibitors.
MX2014011827A (en) 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE ß-LACTAMASE INHIBITORS.
EP2780447A4 (en) Novel isolated bacteriophage having e. coli-specific bactericidal activity and antibacterial composition comprising the same
MX2014014832A (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase.
IN2015DN00598A (en)
TN2015000262A1 (en) Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
MX2017007371A (en) Antibacterial compounds having broad spectrum of activity.
IN2014DN10449A (en)
MX2014015345A (en) Pyranopyridone inhibitors of tankyrase.
WO2014105777A8 (en) Cobicostat dichlohydrate salt
WO2015044434A3 (en) Fluor-9-methyl-β-carbolines
PH12015501428A1 (en) Antibacterial compounds
EP2866569B8 (en) Antimicrobial composition
PT2802558T (en) Compounds having antibacterial activity, process for their preparation and pharmaceutical compositions comprising them
WO2014147578A3 (en) Antibacterial compounds against drug resistant bacteria
WO2014101294A9 (en) Glycopeptide compound or pharmaceutical salt thereof and method for preparing same, and pharmaceutical compositions and applications thereof
UA74648U (en) 1,2,4-triazole derivatives exhibiting antimicrobial activity
WO2014006601A3 (en) Nanoparticle compositions of antibacterial compounds and other uses thereof
UA105703C2 (en) 7-bromo-5-phenyl-3-arylamino-1,2-dihydro-3h-1,4-benzdiazepin-2-ones as analgetic agents
AU2012905697A0 (en) Improved antimicrobial composition
AU2012905670A0 (en) Improved antimicrobial composition